Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Foresite Capital in the transaction. Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company,...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Contineum Therapeutics in the offering, and Sidley Austin represented the underwriters. Contineum Therapeutics, a clinical stage biopharmaceutical company,...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian acted as counsel to Tarsus Pharmaceuticals in the offering, Hogan Lovells acted as regulatory counsel while Knobbe Martens Olson...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented Veradigm Inc. in the transaction, and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented ScienceIO. Veradigm Inc. (NASDAQ: MDRX) (the “Company”),...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Natera, and Davis Polk & Wardwell advised the representatives of the several underwriters on the offering. Natera, Inc....
You must be a Standard 1 Year member to access this content.
